• 1
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 526.
  • 2
    Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405410.
  • 3
    Fisher B, Carbone P, Economou SG, et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975; 292: 117122.
  • 4
    Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988; 319: 16811692.
  • 5
    Anonymous. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352: 930942.
  • 6
    Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976983.
  • 7
    Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17: 14131424.
  • 8
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 9
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 10
    Buzdar AU, Blumenschein GR, Gutterman JU, et al. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979; 242: 15091513.
  • 11
    Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984; 53: 384389.
  • 12
    Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988; 62: 20982104.
  • 13
    Buzdar AU, Hortobagyi GN, Kau SW, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for Stage II or III breast cancer. J Clin Oncol. 1992; 10: 15401546.
  • 14
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of Stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995; 4: 715734.
  • 15
    Assikis V, Buzdar A, Yang Y, et al. A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003; 97: 27162723.
  • 16
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187220.
  • 17
    Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987; 5: 5561.
  • 18
    Chia SK, Speers C, Kang A, et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer in a population based cohort [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 22a.
  • 19
    Arveux P, Grosclaude P, Reyrat E, Velten M, Bardau V, Borella L. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centers between 1980 and 1999 [Abstract]. Proc Am Soc Clin Oncol. 2003; 22: 3437a.